A phase IIa proof-of-pharmacology study assessing MBX-2982
Latest Information Update: 14 Nov 2023
At a glance
- Drugs MBX 2982 (Primary)
- Indications Hypoglycaemia; Type 1 diabetes mellitus
- Focus Therapeutic Use
- 07 Nov 2023 According to a CymaBay Therapeutics media release, Status changed from active, no longer recruiting to completed.
- 10 Aug 2023 ccording to a CymaBay Therapeutics media release, top-line results are expected by year-end 2023.
- 10 Aug 2023 Status changed from recruiting to active, no longer recruiting, according to a CymaBay Therapeutics media release.